Tekmira Pharmaceuticals has made executive appointments to its senior leadership team. Adam Cutler has been named senior vice president, corporate affairs; Dr. Bruce Dorsey has been appointed vice president, chemistry; and Dr. Rene Cornelis Rijnbrand has been named vice president, Biology.  
 
"We are delighted to welcome Adam, Bruce and Rene to our executive team at this exciting time in Tekmira's evolution and emergence as an HBV solutions company," said Dr. Mark J. Murray, Tekmira's president and chief executive officer. "Adam has an unparalleled reputation as a top-ranked biotechnology sell-side analyst and advisor, with extensive experience in capital formation, corporate positioning and reputation management. Bruce and Rene each has more than 10 years of experience in the biopharmaceutical industry, leading high-profile discovery research teams spanning multiple therapeutic areas, with strong focus on virology and HBV."
 
Mr. Cutler joins the company from The Trout Group LLC, where he successfully executed financings and advised a wide range of life science companies on investor relations, business development, and capital raising strategy. He also spent 12 years as a sell-side analyst with firms including Credit Suisse, Canaccord Genuity, JMP Securities, and Banc of America Securities.
 
Dr. Dorsey was most recently vice president, Chemistry with OnCore Biopharma, focusing on HBV and building the company's U.S. operations. Previously, he held senior-level positions with Teva Pharmaceuticals, Cephalon, Locus Discovery and Merck & Co., where his therapeutic focus included virology, oncology, CNS, inflammatory and gastrointestinal disorders, and pain.
 
Dr. Rijnbrand most recently served as vice president and head of Biology at OnCore Biopharma, where he led efforts in virology and immunology to develop curative approaches for chronic HBV infections. Previously, he directed the virology program at Vertex Pharmaceuticals and at Immusol/Itherex Pharmaceuticals.